Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Cancer

U.S. Senate Passes Bill to Improve Cancer Drugs for Children

Washington, DC, August 7, 2017 — Ledyard King reports in USA Today that, until now, drug companies have been free to decide whether to pursue treatments for pediatric cancers as part of their work on adult cancers.

They won’t have much choice going forward.

The Senate on August 3 overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for childhood cancers. Continue reading

Rutgers Cancer Institute of New Jersey Investigators Receive $450K in Fellowship Grants

New Brunswick, NJ, July 27, 2017 — Rutgers Cancer Institute of New Jersey investigators have received $450,000 in funding to support research projects in immunotherapy and basic science research that could impact pancreatic, breast and other cancers.

The Pre- and Post-Doctoral Fellowship Grants were awarded by the New Jersey Commission on Cancer Research (NJCCR).

Eileen White, Ph.D., Rutgers Cancer Institute Deputy Director, Chief Scientific Officer and Associate Director for Basic Science, said, “As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute is dedicated to treatment, prevention, education and research.” Continue reading

VP Joe Biden and Dr. Jill Biden Launch Biden Cancer Initiative; Aims to Make Progress in Cancer Prevention, Detection, Treatment, Care

Dr. Jill Biden and Joe Biden

New York, NY, June 23, 2017 — President Joe Biden and Dr. Jill Biden on June 26 launched the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care.

The launch event was highlighted by Vice President and Dr. Biden joining members of the Biden Cancer Initiative Board of Directors for a conversation about the mission of the Initiative, the issues it will address, and the promise of what they hope to accomplish together.

The Biden Cancer Initiative will develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care, and to reduce disparities in cancer outcomes. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, July 19, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

Vice President Joe Biden and Dr. Jill Biden Launch Biden Cancer Initiative; Aims to Make Progress in Cancer Prevention, Detection, Treatment, Care

Dr. Jill Biden and Vice President Joe Biden

New York, NY, June 28, 2017 — President Joe Biden and Dr. Jill Biden on June 26 launched the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care.

The launch event was highlighted by Vice President and Dr. Biden joining members of the Biden Cancer Initiative Board of Directors for a conversation about the mission of the Initiative, the issues it will address, and the promise of what they hope to accomplish together.

The Biden Cancer Initiative will develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care, and to reduce disparities in cancer outcomes. Continue reading

Trump Names Dr. Norman Sharpless to Serve as Director of National Cancer Institute

Dr. Norman “Ned” Sharpless

Washington, DC, June 19, 2017Science reports that President Donald Trump on June 9 announced his intention to appoint Norman “Ned” Sharpless, M.D., to be the next director of the National Cancer Institute (NCI) in Bethesda, Maryland.

Dr. Sharpless would succeed Harold Varmus as the head of NCI.

Sharpless, 50, is a physician and currently director of the Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill.  He also holds an academic appointment at the university’s school of medicine. Continue reading

Congress Boosts Research Funding in Cancer, Alzheimer’s, Precision Medicine, BRAIN Initiative and ‘Superbugs’

Washington, DC, May 2, 2017 — Ariana Eunjung Cha reports in The Washington Post that Congress unveiled a bipartisan budget late Sunday that contains a number of welcome surprises for researchers who had been panicking since March, when President Trump proposed deep funding cuts for science and health.

Under the deal, the National Institutes of Health will get a $2 billion boost in fiscal year 2017, as it did the previous year.

Trump had proposed cutting the NIH budget by about one-fifth, or $6 billion, in a draft 2018 budget.

Here are some of the big research winners: Continue reading

American Cancer Society and National Cancer Institute Publish Annual Report to the Nation: Cancer Death Rates Continue to Decline

Bethesda, MD, April 11, 2017 — Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975 – 2014.

The Report to the Nation is released each year in a collaborative effort by the American Cancer Society; the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), both parts of the Department of Health and Human Services; and the North American Association of Central Cancer Registries (NAACCR).

The latest report, which was published on March 31, finds that death rates during the period 2010-2014 decreased for 11 of the 16 most common types of cancer in men and for 13 of the 18 most common types of cancer in women, including lung, colorectal, female breast, and prostate cancers. Continue reading

National Cancer Institute: Cancer Moonshot Moves Forward, Bringing Funding Opportunities for Researchers

Bethesda, MD, March 15, 2017Douglas R. Lowy, M.D., Acting Director, National Cancer Institute last month wrote:

The 21st Century Cures Act, which was signed into law in December 2016, authorizes $1.8 billion over 7 years to fund the Beau Biden Cancer Moonshot℠, $300 million of which is available in Fiscal Year 2017.

These funds enable NCI to begin, this fiscal year, implementing cancer research initiatives that align with the goals outlined in last fall’s report from the Cancer Moonshot Blue Ribbon Panel (BRP) and to rapidly build on progress that NCI and its many research partners have achieved over the years. Continue reading

Rutgers Cancer Institute of NJ Resident Receives $1.8M Grant to Explore Chronic Stress Role in Cancer Development

Wenwei Hu, Ph.D.

Wenwei Hu, Ph.D.

New Brunswick, NJ, January 28, 2017 — A five-year, $1.8 million grant (R01CA203965) from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, Ph.D., will support research to further elucidate the mechanisms behind the most frequently mutated gene in human tumors – p53.

The aim is to explore how chronic stress impacts cancer development, especially when cancers containing a mutation in p53, and identify molecular targets that would disrupt the effect of chronic stress on cancer development.

The p53 protein plays a central role in preventing cancer development, as loss of its tumor suppressor function has been shown to contribute greatly to cancer development. Continue reading